Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 3.8% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares were down 3.8% on Monday . The company traded as low as $20.55 and last traded at $20.52. Approximately 29,466 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 226,296 shares. The stock had previously closed at $21.33.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on DNTH shares. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Price Performance

The company has a fifty day simple moving average of $22.34 and a two-hundred day simple moving average of $24.70. The company has a market capitalization of $613.84 million, a P/E ratio of -8.30 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DNTH. MetLife Investment Management LLC boosted its stake in shares of Dianthus Therapeutics by 3.1% in the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after purchasing an additional 433 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Dianthus Therapeutics by 7.4% in the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock valued at $251,000 after purchasing an additional 790 shares in the last quarter. SG Americas Securities LLC lifted its position in Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after buying an additional 814 shares in the last quarter. Barclays PLC lifted its position in Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock worth $933,000 after buying an additional 1,082 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Dianthus Therapeutics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock worth $3,641,000 after buying an additional 1,092 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.